Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPN14770 in Adult Males With Fragile X Syndrome
NCT03569631Phase 2Completed
- Sponsor
- Tetra Therapeutics
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zatolmilast in Fragile X syndrome (FXS), sponsored by Tetra Therapeutics. Started Jul 2018; status: completed.
02
Drugs
zatolmilast
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT03569631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03569631.